OverT Bio received $120,000 in a G-Rex Grant to advance its solid tumor cell therapy development, supported by ScaleReady and its partners.

Nov 22, 2024•9 months ago

Amount Raised

$120,000

Round Type

pre-seed

New YorkBiotechnology

Investors

Cell ReadyBio Techne CorporationWilson Wolf ManufacturingScale Ready

Description

OverT Bio has been awarded a $120,000 G-Rex Grant to support its development of next-generation cell therapies for solid tumors. The grant is part of ScaleReady's $20 million program aimed at advancing cell and gene therapy manufacturing.

Company Information

Company

OverT Bio

Location

430 E 29TH ST 14FL

New York, New York, United States

About

OverT Bio, Inc., is a New York based biotechnology company developing effective and safe cellular therapies for solid tumors. Harnessing innovative pooled functional screening and synthetic genomics platforms (OverTargetTM and OverTCRTM), OverT Bio is uncovering new therapeutic targets and genetic enhancements in an unbiased, data-driven manner to deliver breakthrough medicines to cancer patients underserved by the standard of care.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech